Backed by No­vo and Or­biMed, Thier­ry Abri­b­at hauls in $75M for biotech #3 — a transat­lantic up­start fo­cused on rare dis­eases

No­vo Ven­tures and Or­biMed have joined a syn­di­cate that is kick­start­ing a France/US hy­brid start­up biotech with a pair of drugs aimed at rare dis­eases.

Al­izé Phar­ma 3 — the third in a se­ries of biotech star­tups by the same en­tre­pre­neur — is build­ing teams in Ly­on and Boston as they gear up for clin­i­cal work next year with a $75 mil­lion A round.

Their work is de­vot­ed to AZP-360, a parathy­roid hor­mone (PTH) ana­log out of Mass Gen­er­al de­signed to treat hy­poparathy­roidism. Their oth­er pro­gram is for a pep­tide dubbed AZP-3404 which they hope to use to treat syn­dromes of se­vere in­sulin re­sis­tance — a se­ries of ul­tra-rare dis­eases. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER